Tevogen Bio (NASDAQ:TVGN) Stock Price Up 5.1% – Here’s Why

Tevogen Bio Holdings Inc. (NASDAQ:TVGN – Get Free Report) shares traded up 5.1% on Tuesday. The company traded as high as $7.81 and last traded at $7.81. Approximately 2,793 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 7,942 shares. The stock had previously closed at $7.43.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tevogen Bio in a research report on Friday, July 17th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average target price of $100.00.

Get Tevogen Bio alerts:

Check Out Our Latest Stock Analysis on TVGN

Tevogen Bio Stock Performance

The company’s 50 day moving average price is $6.56 and its 200-day moving average price is $7.00. The company has a market cap of $51.11 million, a price-to-earnings ratio of -1.70 and a beta of 0.17.

Tevogen Bio (NASDAQ:TVGN – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.53) by $1.01.

Tevogen Bio Company Profile

(Get Free Report)

Tevogen Bio Holdings Inc is a clinical-stage biotechnology company focused on developing precision T-cell therapies for patients with viral infections and cancer. The company’s approach uses antigen-specific cytotoxic T lymphocytes designed to recognize and eliminate infected or abnormal cells while seeking to provide an “off-the-shelf” treatment option.

Tevogen’s pipeline is built around its ExacTcell platform, which is intended to support the development and manufacturing of targeted cellular immunotherapies.

See Also

• Five stocks we like better than Tevogen Bio
• Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
• Paychex Plunges, Providing the Entry Investors Have Been Waiting For
• The Case for Buying High-Yield General Mills Just Strengthened
• SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story

Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.